Prelude Therapeutics Company Insiders
PRLD Stock | USD 0.95 0.02 2.20% |
About 85 percent of all Prelude Therapeutics' insiders are aggressively buying. The analysis of the overall insider sentiment regarding Prelude Therapeutics suggests that quite a large number of insiders are very bullish. Prelude Therapeutics employs about 128 people. The company is managed by 14 executives with a total tenure of roughly 299 years, averaging almost 21.0 years of service per executive, having 9.14 employees per reported executive.
Prelude Therapeutics' Insider Buying Vs Selling
85
Selling | Buying |
Latest Trades
2023-05-24 | Krishna Vaddi | Acquired 1000 @ 5.01 | View | ||
2023-05-22 | Orbimed Advisors Llc | Acquired 869565 @ 5.75 | View | ||
2023-04-06 | Jane Huang | Disposed 13280 @ 6.12 | View | ||
2022-12-20 | Krishna Vaddi | Acquired 19188 @ 5.13 | View | ||
2022-12-08 | Laurent Chardonnet | Acquired 10000 @ 4.76 | View | ||
2022-06-01 | Laurent Chardonnet | Acquired 10000 @ 4.23 | View | ||
2021-12-13 | Andrew Combs | Acquired 4000 @ 12.12 | View |
Monitoring Prelude Therapeutics' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Prelude |
Prelude Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.3929) % which means that it has lost $0.3929 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6664) %, meaning that it created substantial loss on money invested by shareholders. Prelude Therapeutics' management efficiency ratios could be used to measure how well Prelude Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of November 23, 2024, Return On Tangible Assets is expected to decline to -0.46. In addition to that, Return On Capital Employed is expected to decline to -0.54. At present, Prelude Therapeutics' Other Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Other Assets is expected to grow to about 11.4 M, whereas Net Tangible Assets are forecasted to decline to about 136.7 M.As of November 23, 2024, Common Stock Shares Outstanding is expected to decline to about 48.3 M. In addition to that, Net Loss is expected to decline to about (109.1 M)
Prelude Therapeutics Workforce Comparison
Prelude Therapeutics is regarded third in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 663. Prelude Therapeutics retains roughly 128 in number of employees claiming about 19% of equities under Health Care industry.
Prelude Therapeutics Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Prelude Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Prelude Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Prelude Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Prelude Therapeutics Notable Stakeholders
A Prelude Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Prelude Therapeutics often face trade-offs trying to please all of them. Prelude Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Prelude Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Edna MD | President Officer | Profile | |
Laurent MBA | Chief Officer | Profile | |
William MD | Senior Development | Profile | |
Naveen Babbar | Senior Medicine | Profile | |
Neelesh MD | VP Devel | Profile | |
Aimee Crombie | Senior Operations | Profile | |
Madhu Pudipeddi | Senior Operations | Profile | |
Lindsey Trickett | Vice Relations | Profile | |
Michele MBA | Chief Officer | Profile | |
Krishna DVM | CEO Founder | Profile | |
Peggy Scherle | Chief Officer | Profile | |
Laurent Chardonnet | Chief Officer | Profile | |
Bryant JD | Chief Secretary | Profile | |
Andrew Combs | Executive Chemistry | Profile |
About Prelude Therapeutics Management Performance
The success or failure of an entity such as Prelude Therapeutics often depends on how effective the management is. Prelude Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Prelude management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Prelude management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.44) | (0.46) | |
Return On Capital Employed | (0.52) | (0.54) | |
Return On Assets | (0.44) | (0.46) | |
Return On Equity | (0.51) | (0.49) |
Please note, the presentation of Prelude Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Prelude Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Prelude Therapeutics' management manipulating its earnings.
Prelude Therapeutics Workforce Analysis
Traditionally, organizations such as Prelude Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Prelude Therapeutics within its industry.Prelude Therapeutics Manpower Efficiency
Return on Prelude Therapeutics Manpower
Revenue Per Employee | 0.0 | |
Revenue Per Executive | 0.0 | |
Net Loss Per Employee | 951.8K | |
Net Loss Per Executive | 8.7M | |
Working Capital Per Employee | 1.7M | |
Working Capital Per Executive | 15.3M |
Complementary Tools for Prelude Stock analysis
When running Prelude Therapeutics' price analysis, check to measure Prelude Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Prelude Therapeutics is operating at the current time. Most of Prelude Therapeutics' value examination focuses on studying past and present price action to predict the probability of Prelude Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Prelude Therapeutics' price. Additionally, you may evaluate how the addition of Prelude Therapeutics to your portfolios can decrease your overall portfolio volatility.
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges |